Stockscreener 앱 받기
8.02
2.30%
0.18
시간 외 거래:
8.02
전일 마감가:
$7.84
열려 있는:
$7.88
하루 거래량:
62,401
Relative Volume:
0.66
시가총액:
$732.34M
수익:
$116.59M
순이익/손실:
$9.88M
주가수익비율:
356.44
EPS:
0.0225
순현금흐름:
$-2.40M
1주 성능:
+13.12%
1개월 성능:
+6.15%
6개월 성능:
-9.58%
1년 성능:
-4.52%
1일 변동 폭
$7.85
$8.05
1주일 범위
$7.03
$8.05
52주 변동 폭
$6.57
$11.78
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(858) 567-7770
주소
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.02 | 715.90M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | Jefferies | Buy |
| 2025-08-26 | 개시 | H.C. Wainwright | Buy |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Growth Recap: Is Gyre Therapeutics Incs ROE strong enoughDip Buying & High Conviction Trade Alerts - baoquankhu1.vn
GYRE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dow Update: Does Gyre Therapeutics Inc offer margin of safetyMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Rate Hike: Is Gyre Therapeutics Inc stock showing strong momentumWeekly Gains Report & Safe Capital Growth Stock Tips - baoquankhu1.vn
GYRE PE Ratio & Valuation, Is GYRE Overvalued - Intellectia AI
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill
Growth Value: How do insiders feel about Gyre Therapeutics IncPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Portfolio Shifts: How do insiders feel about Gyre Therapeutics Inc2026 Major Catalysts & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Rally Mode: Is Gyre Therapeutics Inc a turnaround story2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Will Gyre Therapeutics Inc stock hit new highs in YEAR2026 Spike Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis - Minichart
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday - MarketBeat
Gyre Therapeutics Files NDA in China for F351 - TipRanks
Gyre Therapeutics (GYRE) submits China NDA for Hydronidone in CHB liver fibrosis - Stock Titan
EV Market: What are analysts price targets for Gyre Therapeutics Inc2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2%Time to Sell? - MarketBeat
China grants priority review to Gyre’s liver fibrosis drug By Investing.com - Investing.com India
China grants priority review to Gyre’s liver fibrosis drug - Investing.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - Bitget
Aug Intraday: Is Gyre Therapeutics Inc currently under institutional pressureTrade Ideas & Weekly Top Gainers Alerts - baoquankhu1.vn
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics Announces China’s NMPA Grants Priority - GlobeNewswire
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions - The Globe and Mail
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results - MarketBeat
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE) - theglobeandmail.com
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold - MarketBeat
Gyre Therapeutics 2025 10-K: Revenue $116.6M, Net Income Per Share Decline - TradingView
Gyre Therapeutics (NASDAQ: GYRE) grows China fibrosis base, eyes Hydronidone NDAs - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap DownShould You Sell? - MarketBeat
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics, Inc. Provides Revenues Outlook for 2026 - marketscreener.com
GYRE | Gyre Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics (NASDAQ: GYRE) details F351, ETUARY and CG001419 outlook at investor conference - Stock Titan
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Gyre Therapeutics Inc 주식 (GYRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 27 '25 |
Sale |
10.28 |
2,000 |
20,560 |
2,806,642 |
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
2.69%
0.25%
자본화:
|
볼륨(24시간):